Skip to main content

Table 1 Baseline characterstics of participating diabetic kidney disease patients

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

  Microalbuminuria Macroalbuminuria
TSF (n = 15) Placebo (n = 15) P Value TSF (n = 15) Placebo (n = 15) P Value
Age (yr) 56.1 ± 12.5 51.8 ± 8.5 .382 55.5 ± 8.2 58.0 ± 10.8 .522
Male/Female 9/6 7/8 .384 6/9 5/10 .400
BMI (kg/m2) 26.1 ± 3.7 26.0 ± 3.9 .950 25.9 ± 3.0 27.3 ± 2.9 .271
Blood pressure
 Systolic (mmHg) 131.9 ± 7.8 128.3 ± 5.6 .259 130.1 ± 8.3 131.1 ± 9.3 .777
 Diastolic (mmHg) 81.6 ± 6.4 76.2 ± 10.1 .142 78.6 ± 7.4 82.0 ± 4.9 .231
Laboratory variables
 FBG (mmol/L) 6.7 ± 0.9 5.7 ± 1.0 .097 6.9 ± 1.5 6.8 ± 0.7 .752
 A1C (%) 6.7 ± 0.6 6.5 ± 0.6 .065 6.7 ± 1.0 6.5 ± 1.3 .579
 TG (mmol/L) 2.5 ± 1.6 2.2 ± 1.2 .617 2.7 ± 1.8 2.2 ± 1.0 .528
 TC (mmol/L) 5.2 ± 0.9 4.9 ± 1.6 .532 5.2 ± 0.9 5.6 ± 1.2 .545
 LDL (mmol/L) 3.0 ± 0.9 3.2 ± 1.4 .729 3.0 ± 1.2 3.8 ± 1.6 .293
 HDL (mmol/L) 1.3 ± 0.6 1.0 ± 0.3 .091 1.3 ± 0.4 1.5 ± 0.3 .182
 ALT (U/L) 26.2 ± 12.6 22.2 ± 9.1 .417 22.2 ± 8.7 22.9 ± 7.8 .835
 AST (U/L) 22.4 ± 7.8 17.2 ± 5.5 .102 20.3 ± 5.7 22.5 ± 8.5 .443
  1. Values expressed as mean ± SD
  2. Abbreviations: ALT alanine aminotransferase, A1C glycosylated hemoglobin, AST aspartate aminotransferase, BMI body mass index, FBG fasting blood glucose, HDL high density lipoprotein, LDL low density lipoprotein, TC total cholesterol, TG triglyceride